Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER is an intravenous solution that provides electrolytes and calories. Dextrose serves as a source of calories and water for hydration. Electrolytes (sodium, potassium, magnesium, chloride, acetate) help maintain acid-base balance and osmotic pressure. Acetate is a bicarbonate precursor that helps correct metabolic acidosis.
Isolyte E with Dextrose 5% provides isotonic fluid, electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate), and calories (dextrose). Dextrose supplies glucose for cellular energy, electrolytes maintain acid-base balance and osmotic pressure, and acetate/gluconate serve as bicarbonate precursors to correct metabolic acidosis.
Parenteral replacement of fluid and electrolytes,Caloric supplementation in patients requiring IV therapy,Maintenance of hydration and electrolyte balance
Fluid and electrolyte replacement in patients with normal or mildly depleted intravascular volume,Treatment and prevention of hypokalemia,Metabolic acidosis correction,Caloric supplementation when peripheral parenteral nutrition is indicated
Intravenous infusion; dose is individualized based on fluid and electrolyte requirements. Typical adult dose is 500-1000 m L per hour initially, then adjusted to clinical response.
Intravenous infusion; dose based on electrolyte deficits and maintenance requirements; typical adult maintenance: 50-100 m L/hour, up to 2-3 L/day.
Not applicable (isotonic solution components; glucose half-life ~1.5-2 h in healthy; electrolytes are distributed and excreted per homeostasis)
Not applicable (dextrose and electrolytes are endogenous substances; distribution and elimination are rapid, with a functional half-life of minutes to hours depending on infusion rate and renal function).
Dextrose undergoes glycolysis and subsequent metabolism via the citric acid cycle. Electrolytes are not metabolized but are excreted or retained as needed by the kidneys. Acetate is metabolized in the liver and peripheral tissues to bicarbonate.
Dextrose is metabolized via glycolysis and the citric acid cycle. Acetate is metabolized primarily in the liver and muscle to bicarbonate. Gluconate is converted to glucose or metabolized via the pentose phosphate pathway.
Renal: 90% (as water, electrolytes, and glucose), Fecal: <5%, Biliary: <1%
Renal: 100% (as free water and electrolytes, not metabolized). Biliary/Fecal: negligible.
<5% (no significant binding; electrolytes and glucose are free)
Negligible (<5%) for dextrose and electrolytes; no specific binding proteins.
For water: ~0.6 L/kg (total body water); for electrolytes: variable (sodium ~0.4 L/kg, potassium ~0.5 L/kg); glucose ~0.2 L/kg
Dextrose: ~0.2 L/kg (total body water); Electrolytes: ~0.4 L/kg (extracellular fluid). Clinical meaning: distributes throughout total body water.
Intravenous: 100%
Intravenous: 100%.
Contraindicated in severe renal impairment (GFR < 30 m L/min) due to risk of hyperkalemia and metabolic acidosis. In mild-moderate impairment (GFR 30-89 m L/min), use with caution and monitor electrolytes, reduce infusion rate.
Monitoring of electrolytes and volume status required; dosage adjustment not standardized; avoid in severe renal impairment (e GFR <30 m L/min/1.73 m²) due to risk of hyperkalemia and fluid overload.
No specific adjustment for Child-Pugh class A or B. In severe hepatic impairment (Child-Pugh class C), use with caution due to risk of fluid overload and electrolyte imbalances; monitor closely.
No specific adjustment recommended; monitor electrolytes and acid-base balance; caution in severe hepatic impairment due to altered fluid clearance.
Weight-based dosing: 10-20 m L/kg intravenously as a bolus for rehydration, then maintenance at 100-150 m L/kg/day for infants, 80-120 m L/kg/day for children, adjusted based on clinical status.
Weight-based: 100-150 m L/kg/day for maintenance; adjust for ongoing losses; use with caution in neonates and children with renal impairment.
Elderly patients may have decreased renal function; use with caution, monitor renal function and electrolytes. Start at lower end of dose range (e.g., 100-500 m L/hour) and titrate slowly.
Consider reduced starting rates due to decreased renal function and increased risk of fluid overload; monitor electrolytes and volume status closely; adjust rate based on comorbidities.
Not for use in patients with known hypersensitivity to any component. Do not administer unless solution is clear and container undamaged. Discard unused portion.
NOT FOR USE IN HYPERLACTATEMIA, SEVERE METABOLIC ALKALOSIS, OR SEVERE HEPATIC FAILURE; CONTAINS ALUMINUM WHICH MAY BE TOXIC WITH PROLONGED USE IN RENAL IMPAIRMENT; ADDITIVES MAY BE INCOMPATIBLE, CONSULT PHARMACIST.
Monitor serum electrolytes, fluid balance, and renal function during prolonged therapy,Use with caution in patients with heart failure, renal impairment, or conditions predisposing to hyperkalemia,Avoid rapid infusion to prevent hyperglycemia and osmotic diuresis,Risk of phlebitis and infection at injection site
Monitor serum electrolytes, fluid balance, and blood glucose. Use with caution in patients with heart failure, renal impairment, hepatic disease, or hyperglycemia. Hypersensitivity reactions may occur. Avoid rapid or large-volume infusion in patients with impaired glucose tolerance.
Hyperkalemia,Hypernatremia,Hyperglycemia,Severe metabolic acidosis,Patients with known hypersensitivity to any component,Do not administer if solution is cloudy or contains precipitate
Hypernatremia, hyperkalemia, hypermagnesemia, hypercalcemia, hyperlactatemia, severe metabolic alkalosis, severe hepatic failure, hyperglycemic states, anuria, or known hypersensitivity to any component.
No known direct food interactions. However, patients should maintain a balanced diet as recommended by their physician. Avoid excessive intake of potassium-rich foods or salt substitutes if at risk of hyperkalemia, especially with impaired renal function.
No known food interactions. However, patients with diabetes should be aware of dextrose content which affects blood glucose. Dietary potassium or magnesium restriction may be necessary if electrolyte imbalances occur.
No teratogenic risk in any trimester. Isolyte M with Dextrose 5% is a balanced electrolyte and glucose solution. Dextrose and electrolytes are endogenous substances; no fetal harm is expected with appropriate maternal administration. However, maternal hyperglycemia (e.g., from excessive dextrose) may cause fetal hyperinsulinism and rebound neonatal hypoglycemia, especially in third trimester.
No evidence of teratogenicity in animal studies or human data. Dextrose and electrolytes are essential nutrients; no structural anomalies attributed. However, hyperglycemia in uncontrolled maternal diabetes may cause fetal malformations. Use cautiously in gestational diabetes.
Safe during breastfeeding. Dextrose and electrolytes are normal blood constituents. Glucose is actively transported into breast milk; M/P ratio approximately 1.0. No adverse effects on nursing infants expected.
Dextrose and electrolytes pass into breast milk but are normal milk constituents. No adverse effects expected in term infants. M/P ratio not determined as these are endogenous substances. Consider maternal fluid/electrolyte status.
No dose adjustment required for pregnancy. Infusion rate should be guided by maternal fluid and electrolyte needs, blood glucose levels, and clinical status. During labor, monitor for fluid overload; consider reduced rate if oxytocin is co-administered. Increased glomerular filtration rate in pregnancy may necessitate adjustments in electrolyte compositions (e.g., potassium) but standard formulation remains appropriate.
No specific dose adjustment needed. Monitor for volume expansion in pregnancy (increased intravascular space). Adjust rate based on maternal glucose, electrolytes, and clinical response. Avoid excess dextrose in gestational diabetes.
ISOLYTE M with dextrose 5% is a maintenance IV solution containing electrolytes and dextrose. Monitor serum electrolytes and glucose, especially in patients with renal impairment or diabetes. Do not administer simultaneously with blood through same tubing due to risk of hemolysis. Use inline filter if particulate contamination is suspected. Inspect for leaks and precipitate before administration. Adjust flow rate based on clinical status and fluid balance.
ISOLYTE E W/ DEXTROSE 5% is an isotonic, balanced electrolyte solution with 5% dextrose for parenteral replacement of fluid and electrolytes. It contains potassium, magnesium, and acetate (bicarbonate precursor). Avoid in patients with hyperkalemia, hypermagnesemia, or metabolic alkalosis. Monitor serum electrolytes, glucose, and renal function. Use with caution in heart failure, renal impairment, and patients at risk for fluid overload. Do not administer if cloudy or precipitate present. Discard any unused portion.
This solution provides fluids, sugar, and electrolytes to maintain body balance.,Inform your healthcare provider if you have diabetes, kidney problems, or heart disease.,Tell your doctor if you experience swelling, shortness of breath, or irregular heartbeat during infusion.,Avoid consuming extra salt or potassium without medical advice while receiving this treatment.
This solution provides fluids, sugar, and electrolytes to correct imbalances.,Your healthcare team will monitor your blood sugar and electrolyte levels during treatment.,Report any symptoms like swelling, shortness of breath, or changes in urination.,This medication is given only in a hospital or clinic setting by a healthcare professional.,Tell your doctor if you have any allergies, especially to corn (dextrose source).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER is an intravenous solution that provides electrolytes and calories. Dextrose serves as a source of calories and water for hydration. Electrolytes (sodium, potassium, magnesium, chloride, acetate) help maintain acid-base balance and osmotic pressure. Acetate is a bicarbonate precursor that helps correct metabolic acidosis.. ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte E with Dextrose 5% provides isotonic fluid, electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate), and calories (dextrose). Dextrose supplies glucose for cellular energy, electrolytes maintain acid-base balance and osmotic pressure, and acetate/gluconate serve as bicarbonate precursors to correct metabolic acidosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; dose is individualized based on fluid and electrolyte requirements. Typical adult dose is 500-1000 m L per hour initially, then adjusted to clinical response.. The standard adult dose of ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; dose based on electrolyte deficits and maintenance requirements; typical adult maintenance: 50-100 m L/hour, up to 2-3 L/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. No teratogenic risk in any trimester. Isolyte M with Dextrose 5% is a balanced electrolyte and glucose solution. Dextrose and electrolytes are endogenous substances; no fetal harm . ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. No evidence of teratogenicity in animal studies or human data. Dextrose and electrolytes are essential nutrients; no structural anomalies attributed. However, hyperglycemia in unco. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.